文献速递肺栓塞与肺血管病

Selexipag 用于不可手术或持续/复发 CTEPH 的疗效与安全性(SELECT 随机试验)

Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial).
PubMed 文献 · Eur Respir J · 2024-10-03

SELECT 是首个在不可手术或持续/复发慢性血栓栓塞性肺动脉高压(CTEPH)患者中评估 selexipag 联合标准治疗的全球随机对照试验。128 例患者随机分组,主要终点为第 20 周肺血管阻力(PVR)较基线的百分比变化。因主要终点无统计学显著差异(几何最小二乘均值比 0.95,95%CI 0.84-1.07;p=0.412),研究因无效而终止;安全性数据与 selexipag 已知特征一致。

要点

  • SELECT 因主要终点 PVR 无显著改善而因无效终止。
  • selexipag 组不良事件报告率 98.4%,安慰剂组 82.8%。
  • 安全性数据与 selexipag 已知特征一致,未发现新安全信号。

核心结论

  • SELECT 研究因无效而终止,selexipag 对主要终点 PVR 未观察到治疗效果。
  • 安全性数据与 selexipag 已确定的安全性特征一致,未发现新的安全信号。

研究设计与样本

  • SELECT 为多中心、随机、双盲、安慰剂对照、平行分组、组序贯、3 期研究(ClinicalTrials.gov: NCT03689244)。
  • 纳入 ≤85 岁、WHO 功能分级 I-IV、6 分钟步行距离 100-450 m 的成人患者,按 1:1 随机接受 selexipag(200-1600 µg 每日两次滴定至个体最大耐受剂量)联合标准治疗或安慰剂联合标准治疗。
  • 患者分入血流动力学集(前 91 例随机患者接受右心导管检查,第 20 周)或非血流动力学队列(其余患者,无需右心导管检查)。
  • 筛查 321 例,随机 128 例(血流动力学集 n=91:selexipag n=47,安慰剂 n=44)。
  • 血流动力学集中,29 例(31.9%)有既往肺动脉内膜剥脱术(PEA),20 例(22.0%)有球囊肺动脉成形术(BPA),14 例(15.4%)同时有 PEA 和 BPA,28 例(30.8%)为不可手术。

主要发现

  • 主要终点第 20 周 PVR 较基线百分比变化无统计学显著差异(组间几何最小二乘均值比 0.95,95%CI 0.84-1.07;p=0.412)。
  • 独立数据监测委员会因无效建议停止研究。
  • 不良事件在 selexipag 组报告于 63 例(98.4%)患者,安慰剂组 53 例(82.8%)患者。

临床怎么用

  • 对于不可手术或持续/复发 CTEPH 患者,不推荐基于本试验结果使用 selexipag 以改善 PVR。
  • selexipag 在该人群中的安全性特征与已知一致,但疗效未获证实。

局限性

  • 研究因无效提前终止,可能影响结果解读。
  • 主要终点为第 20 周 PVR 变化,非临床结局终点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: SELECT was the first global randomised controlled trial of selexipag with standard of care in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension. METHODS: SELECT was a multicentre, randomised, double-blind, placebo-controlled, parallel-group, group-sequential, phase 3 study (ClinicalTrials.gov: NCT03689244). Adults aged ≤85 years in World Health Organization Functional Class I-IV, with a 6-min walk distance of 100-450 m, were randomised (1:1) to receive selexipag (200-1600 µg twice daily titration until individual maximum tolerated dose)+standard of care or placebo+standard of care. Patients were recruited into the haemodynamic set (first 91 randomised patients to undergo right heart catheterisation (RHC); week 20) or non-haemodynamic cohort (remaining patients, no RHC required). The primary end-point was percent of baseline pulmonary vascular resistance (PVR; week 20). Safety was also assessed. RESULTS: Of 321 patients screened, 128 were randomised (haemodynamic set n=91 (selexipag n=47; placebo n=44)). In the haemodynamic set, 29 (31.9%) patients had previous pulmonary endarterectomy (PEA), 20 (22.0%) balloon pulmonary angioplasty (BPA), and 14 (15.4%) both PEA and BPA; 28 (30.8%) were inoperable. The independent data monitoring committee recommended to stop the study for futility as no statistically significant difference was observed for the primary end-point (between-treatment geometric least squares mean ratio of PVR: 0.95, 95% CI 0.84-1.07; p=0.412). Adverse events were reported in 63 (98.4%) and 53 (82.8%) patients for selexipag and placebo, respectively. CONCLUSIONS: SELECT was discontinued for futility, as no treatment effect on the primary end-point (PVR) was observed. Safety data were consistent with the established safety profile of selexipag, with no new safety signals identified.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Kim NH, Channick R, Delcroix M, et al. Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial). Eur Respir J. 2024. PMID: 39326918. doi:10.1183/13993003.00193-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。